Can these high-flying biotech stocks keep the momentum going?
News & Analysis: Iovance Biotherapeutics, Inc.
Good news gave these stocks even better gains than the overall market.
The company's promising immunotherapy approach delivered impressive data in multiple studies.
IOVA earnings call for the period ending March 31, 2019.
Investors are excited about a chance to move forward faster than expected.
IOVA earnings call for the period ending December 31, 2018.
Recent gains, which didn't make much sense to begin with, were very short-lived.
Find out which of these stocks had the best gains.
A key clinical update sent Iovance's shares spiraling downward today.
They all shared one important common denominator.